Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Effects of nilotinib on regulatory T cells: the dose matters

Figure 2

Nilotinib does not hamper immunosuppressive capacity of CD4+CD25+ T cells at clinical relevant doses. Panel A: Purified CD4+CD25+ T cells or CD4+CD25- T cells (Teff) were labeled with CFSE. CFSE+-labeled CD4+CD25- T cells were stimulated with anti-CD3 and anti-CD28 in the presence or absence of nilotinib. The proliferation of CD4+CD25- T cells was measured by the division of CFSE. Combined results from three independent experiments were shown. Panel B: CD4+CD25+ T cells were first incubated with different concentrations of nilotinib overnight in the presence of IL-2. After washing cells for three times, CD4+CD25+ T cells were co-cultured with CFSE+-labeled CD4+CD25- T cells as a ratio of 1:1. Cell division was assessed by levels of CFSE dilution.

Back to article page